Short answer first, then the reasoning. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.
My problem is day one and day two, not the week as a whole, which is why splitting appealed to me before I read anything about it.
What I am trying to establish is what the pharmacokinetic argument against splitting a weekly dose actually is, since intuitively it should smooth the curve.
I would rather have one careful answer than five confident ones.
LabKate said:The mechanism that matters here is not stomach emptying, it is central.
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.NateNeph said:My problem is day one and day two, not the week as a whole, which is why splitting appealed to me before I read anything about it.
Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.
From the other side of the consultation, briefly.
Dose splitting update on split dosing: instead of 2.4mg once weekly, I've been doing 1.2mg twice weekly (Mon/Thu) with my doctor's approval. The appetite suppression is more consistent and side effects are noticeably milder.
Not medical advice, just sharing what's worked for me. Discuss with your provider before trying this.